{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:59:44Z","timestamp":1790135984990,"version":"4.0.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Relebactam (REL [MK-7655]) is a novel class A\/C \u03b2-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL restores imipenem activity against some resistant strains of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas<\/jats:named-content>\n            . In this multicenter, double-blind, controlled trial (NCT01506271), subjects who were \u226518 years of age with complicated intra-abdominal infection were randomly assigned (1:1:1) to receive 250 mg REL, 125 mg REL, or placebo, each given intravenously (i.v.) with 500 mg imipenem-cilastatin (IMI) every 6 h (q6h) for 4 to 14 days. The primary efficacy endpoint was the proportion of microbiologically evaluable (ME) subjects with a favorable clinical response at discontinuation of i.v. therapy (DCIV). A total of 351 subjects were randomized, 347 (99%) were treated, and 255 (73%) were ME at DCIV (55% male; mean age, 49 years). The most common diagnoses were complicated appendicitis (53%) and complicated cholecystitis (17%). Thirty-six subjects (13%) had imipenem-resistant Gram-negative infections at baseline. Both REL doses plus IMI were generally well tolerated and demonstrated safety profiles similar to that of IMI alone. Clinical response rates at DCIV were similar in subjects who received 250 mg REL plus IMI (96.3%) or 125 mg REL plus IMI (98.8%), and both were noninferior to IMI alone (95.2%; one-sided\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). The treatment groups were also similar with respect to clinical response at early and late follow-up and microbiological response at all visits. Pharmacokinetic\/pharmacodynamic simulations show that imipenem exposure at the proposed dose of 500 mg IMI with 250 mg REL q6h provides coverage of &gt;90% of carbapenem-resistant bacterial strains.\n          <\/jats:p>","DOI":"10.1128\/aac.00633-16","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T02:53:53Z","timestamp":1470711233000},"page":"6234-6243","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":175,"title":["Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection"],"prefix":"10.1128","volume":"60","author":[{"given":"Christopher","family":"Lucasti","sequence":"first","affiliation":[{"name":"South Jersey Infectious Disease, Somers Point, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"Vasile","sequence":"additional","affiliation":[{"name":"University of Medicine &amp; Pharmacy, Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorel","family":"Sandesc","sequence":"additional","affiliation":[{"name":"University of Medicine &amp; Pharmacy, Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatas","family":"Venskutonis","sequence":"additional","affiliation":[{"name":"Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McLeroth","sequence":"additional","affiliation":[{"name":"Covance Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Lala","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Rizk","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Losada","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pedley","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kartsonis","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/533452"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq174"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01773-09"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/651670"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70143-2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70054-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.14.40.19349-en"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.14.13.19163-en"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-0921-3"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-0896-0"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70018-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)02075-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181c9c118"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2005.08.014"},{"key":"e_1_3_3_17_2","volume-title":"Abstr","author":"Young K","year":"2010","unstructured":"Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorso KL, Park Y-W, Ogawa AM, Wisniewski D, Hermes J, Blizzard TA, Hammond ML, Motyl MR. 2010. In vitro activity of the class A and C \u03b2-lactamase inhibitor MK-7655, abstr F1-2139. Abstr 50th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178"},{"key":"e_1_3_3_19_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"Young K","year":"2015","unstructured":"Young K, Motyl M. 2015. Retrospective analysis of the effect of MK-7655 (relebactam) on imipenem non-susceptible Pseudomonas aeruginosa and KPC-expressing Enterobacteriaceae, abstr C-156. Abstr 55th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_3_21_2","volume-title":"Abstr","author":"Powles MA","year":"2010","unstructured":"Powles MA, Galgoci A, Misura A, Liberator P, Hammond M. 2010. In vivo efficacy of the beta-lactamase inhibitor, MK-7655, in combination with imipenem in murine models of infection, abstr F1-2140. Abstr 50th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_22_2","volume-title":"Abstr","author":"Wu J","year":"2014","unstructured":"Wu J, Racine F, Rizk ML, Wismer MK, Harradine P, Young K, Motyl M. 2014. Exploring PK\/PD relationship of a novel beta-lactamase inhibitor MK-7655 in combination with imipenem in a hollow fiber infection model, abstr P1740. Abstr 24th Annu Eur Congress Clin Microbiol Infect Dis."},{"key":"e_1_3_3_23_2","volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Tang W","year":"2010","unstructured":"Tang W, Dingley K, Blizzard L, Young K, Motyl M. 2010. MK-7655 human dose projection based on its pharmacokinetics in preclinical species, abstr F1-2141. Abstr 50th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03706-14"},{"key":"e_1_3_3_25_2","volume-title":"Abstr","author":"Rizk ML","year":"2012","unstructured":"Rizk ML, Ahmed GF, Young K, Motyl M, Butterton J, Racine F, Wu J, Li C, Wenning L. 2012. A semi-mechanistic pharmacokinetic\/pharmacodynamic (PK\/PD) model for MK-7655, a novel beta-lactamase inhibitor (BLI) for use in combination with imipenem\/cilastatin, abstr A-1763. Abstr 52nd Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_26_2","volume-title":"Abstr","author":"Young K","year":"2012","unstructured":"Young K, Hackel M, Lascols C, Bouchillon S, Badal R. 2012. Response to imipenem plus MK-7655, a novel \u03b2-lactamase inhibitor, in a surveillance study population of P. aeruginosa from SMART 2009, abstr C2-724. Abstr 52nd Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690508"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0506-7"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/649554"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"e_1_3_3_31_2","volume-title":"Guidance for industry: complicated intra-abdominal infections: developing drugs for treatment","author":"Center for Drug Evaluation and Research","year":"2015","unstructured":"Center for Drug Evaluation and Research. 2015. Guidance for industry: complicated intra-abdominal infections: developing drugs for treatment. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm321390.pdf."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.2.335"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.3.365"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00633-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00633-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:08:50Z","timestamp":1645484930000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00633-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/AAC.00633-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00633-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}